FDA Approved: GENVOYA — Original Application (Gilead Sciences, Inc.)

View source ↗

Summary

FDA approved GENVOYA as a new fixed-dose combination tablet for HIV-1 infection, combining elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Genvoya (elvitegravir; cobicistat; emtricitabine; tenofovir alafenamide)

Snippet

ORIG AP for GENVOYA (ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE)